SBI Securities Co. Ltd. Makes New $28,000 Investment in AngioDynamics, Inc. (NASDAQ:ANGO)

SBI Securities Co. Ltd. purchased a new position in AngioDynamics, Inc. (NASDAQ:ANGO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,005 shares of the medical instruments supplier’s stock, valued at approximately $28,000.

Other hedge funds have also added to or reduced their stakes in the company. R Squared Ltd bought a new stake in AngioDynamics in the fourth quarter worth $49,000. US Bancorp DE lifted its stake in AngioDynamics by 1,938.0% in the fourth quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 6,376 shares during the last quarter. Quarry LP lifted its stake in AngioDynamics by 40.9% in the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 2,471 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in AngioDynamics in the third quarter worth $86,000. Finally, SG Americas Securities LLC increased its position in shares of AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock valued at $147,000 after acquiring an additional 2,832 shares during the period. 89.43% of the stock is owned by institutional investors.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright boosted their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Trading Up 3.1 %

ANGO stock opened at $9.40 on Thursday. The firm’s 50-day moving average price is $10.82 and its two-hundred day moving average price is $8.61. AngioDynamics, Inc. has a 12-month low of $5.26 and a 12-month high of $13.50. The stock has a market capitalization of $380.38 million, a price-to-earnings ratio of -1.67 and a beta of 0.57.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same quarter in the previous year, the company earned ($0.05) earnings per share. The company’s revenue for the quarter was down .1% compared to the same quarter last year. Equities analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.